AIM2 as a negative regulator of renal ischemia/reperfusion injury

项目概述：该提案研究了一种关键的细胞质先天免疫受体， 模式识别受体AIM 2调节NLRP 3炎性体的激活，从而保护 肾小管上皮细胞（RTE）损伤。该项目对急性肾损伤具有重要意义， 并导致慢性肾脏疾病的负担。 广泛/长期目标：拟议研究的长期目标是确定如何激活 AIM 2在缺血再灌注损伤的情况下调节肾脏中的损伤反应。 目的1探讨AIM 2如何调节RTE中的NLRP 3炎性小体（一种已被充分描述的肾IR损伤的触发因素 细胞（最容易受到肾IR损伤的细胞类型），通过定义AIM 2调节的机制， NLRP 3炎性小体引发、组装;以及随后的IL 1b/IL 18释放和细胞凋亡。 目的2侧重于了解AIM 2在体内肾脏中的相对作用。这方面的实验将 广泛评估肾脏特异性损伤介质与炎症损伤介质 允许在WT宿主中研究aim 2-/-肾的损伤应答的移植模型，和WT肾 在aim 2-/-宿主中研究损伤。 项目的健康相关性：如果本提案的目标得到满足，我们将了解AIM 2如何作为一个 肾脏损伤反应的负调节因子。这些知识对于理性的发展至关重要。 用于在缺氧的临床情况下预防或改善肾损伤的靶向治疗 预期。关注缺血性肾损伤的最早期事件， 治疗策略

Project Summary: This proposal studies how activation of a key cytoplasmic innate immune receptor, the pattern recognition receptor AIM2, regulates activation of the NLRP3 inflammasome and thus protects from renal tubular epithelial cell (RTE) injury. The project is highly significant for acute kidney injury, which occurs frequently and leads to the burden of chronic kidney disease. Broad/long-term objectives: The long-term goals of the proposed research are to define how activation of AIM2 regulates injury responses in the kidney in the setting of ischemia reperfusion injury. Aim 1 asks how AIM2 regulates the NLRP3 inflammasome (a well-described trigger of renal IR injury) in RTE cells (the cell type most vulnerable to renal IR injury), by defining the mechanisms by which AIM2 regulates NLRP3 inflammasome priming, assembly; and subsequent release of IL1b/IL18 and pyroptosis. Aim 2 focuses on understanding the relative role of AIM2 in the kidney in vivo. The experiments in this aim will broadly assess kidney-specific mediators of injury vs. inflammatory mediators of injury using a kidney transplant model that allows injury responses of the aim2-/- kidney to be studied in a WT host, and WT kidney injury to be studied in the aim2-/- host. Health Relatedness of Project: If the aims of this proposal are met we will learn how AIM2 participates as a negative regulator of injury responses in the kidney. This knowledge is crucial for the development of rational targeted therapies for prevention or amelioration of renal injury in clinical situations where hypoxia is anticipated. Focusing on the earliest events of ischemic kidney injury holds the greatest promise for effective therapeutic strategies.